Xilio Therapeutics grants inducement stock options for 205,895 shares at $8.91 each
XLO•Xilio Therapeutics granted inducement options covering 205,895 shares, including 105,000 for new Chief Medical Officer Yariv Houvras, at an $8.91 exercise price effective Oct. 1, 2026.
1. Option grant details
The options have a 10-year term; 25% vest after one year, with the remainder vesting monthly over the following 36 months. The $8.91 exercise price matched Xilio’s Oct. 1 closing price.
